IPHA stock forecast, quote, news & analysis
Innate Pharma SA is a clinical-stage biotechnology company... Show more
Innate Pharma (IPHA) Stock Analysis: Clinical Readouts and Cash Runway Set the 2027 Agenda
Key Takeaways
- Innate Pharma (IPHA) shares traded near $1.44 in early November 2026, down roughly 5% from the closing level of about $1.52 recorded one month earlier.
- The stock has trended lower over the recent quarter, sliding from about $2.08 in early September as investors weighed an event-driven clinical timeline and a sub-$2 trading range.
- The company's most immediate catalyst is Phase 1 dose-escalation data for its Nectin-4 antibody-drug conjugate IPH4502, set for presentation at the ENA 2026 symposium on November 18.
- A strategic partnership with Sobi covering lacutamab brought a $75 million upfront payment and strengthened the balance sheet, extending the cash runway into early 2028.
- The AstraZeneca-led PACIFIC-9 Phase 3 trial for monalizumab now expects topline data in the first half of 2027, a shift from the previously guided second half of 2026.
- As a clinical-stage biotech, Innate Pharma generates partnership-based revenue rather than product sales, leaving its valuation tied closely to pipeline milestones and readouts.
- For additional context on valuation and expectations, explore the company's Price Targets, Earnings, and Forecast pages.
- For automated, data-driven trading ideas, explore Trending AI Robots.
Current Market Snapshot
Innate Pharma S.A. (NASDAQ: IPHA) has spent much of late 2026 in a declining channel, with the American depositary shares trading well below their 52-week high and near the lower end of a wide multi-month range. The stock closed around $1.44 in the first week of November, roughly 5% below the prior month's level and more than 30% below the levels seen in early September. Trading volume remains relatively thin for a Nasdaq-listed ADR, and the shares have shown sensitivity to clinical timeline updates rather than broad-market moves. Investor sentiment reflects the typical profile of a clinical-stage oncology developer: cautious optimism about upcoming data readouts balanced against binary-risk exposure and a balance sheet that must be managed carefully between milestones.
Innate Pharma (IPHA) Business Overview and Competitive Position
Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on immuno-oncology and the development of therapeutic antibodies designed to harness the innate immune system against cancer. The company is a recognized pioneer in natural killer (NK) cell biology and has built expertise in the tumor microenvironment, tumor antigens, and antibody engineering.
The pipeline is anchored by three priority programs. Lacutamab, an anti-KIR3DL2 antibody, is advancing through a confirmatory Phase 3 trial in cutaneous T-cell lymphoma under a partnership with Sobi. IPH4502, a Nectin-4-targeting antibody-drug conjugate, is in Phase 1 development for advanced solid tumors. Monalizumab, an anti-NKG2A antibody, is being co-developed with AstraZeneca (AZN) in non-small cell lung cancer. The company also maintains research and licensing relationships with partners including Sanofi (SNY). With no marketed products, revenue comes primarily from government research financing and collaboration agreements, making clinical execution the central driver of value.
Recent Developments Driving IPHA
In its third-quarter 2026 business update, Innate Pharma reported cash, cash equivalents, and financial assets of €96.8 million as of September 30, 2026. That figure incorporates the $75 million upfront payment from the Sobi transaction and €30 million in gross proceeds from a private placement of ordinary shares completed in August. Management indicated the balance sheet provides financial visibility through the end of the first quarter of 2028.
The Sobi partnership, announced in August, granted Sobi an exclusive license for lacutamab in T-cell lymphomas and triggered the initiation of the TELLOMAK-3 Phase 3 study, with first-patient dosing targeted for the first quarter of 2027. Innate Pharma also plans to submit an accelerated-approval filing for lacutamab in Sézary syndrome in the second half of 2027.
Separately, AstraZeneca updated the timeline for the PACIFIC-9 Phase 3 trial evaluating durvalumab with monalizumab or oleclumab in unresectable Stage III non-small cell lung cancer, moving the expected topline readout to the first half of 2027. The shift reflects the event-driven nature of the study. Near term, investors are focused on the November 18 presentation of Phase 1 IPH4502 dose-escalation data at the ENA symposium, where preliminary antitumor activity and safety observations are expected to be detailed.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots drawn from a much larger universe of automated strategies. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this featured section. The bots vary widely in strategy, holding timeframe, and performance metrics, allowing traders to compare approaches that range from short-term momentum models to longer-horizon trend systems. For investors following names such as Innate Pharma, the page provides a way to see how quantitative, rules-based strategies are positioning across the market and to identify bots aligned with a given outlook or risk tolerance.
2026 Outlook and What Investors Should Watch
The most important near-term event for Innate Pharma is the November 18 presentation of IPH4502 Phase 1 dose-escalation data, which could shape the antibody-drug conjugate program's development path and competitive positioning in the Nectin-4 space. Beyond that, investors will monitor the first patient dosing in the TELLOMAK-3 trial during the first quarter of 2027, the planned accelerated-approval filing for lacutamab in Sézary syndrome in the second half of 2027, and the PACIFIC-9 monalizumab topline readout now expected in the first half of 2027.
Key risks include the inherent binary nature of clinical readouts, execution on the TELLOMAK-3 trial timeline, and the company's dependence on milestone and partnership payments to fund operations. Macroeconomic factors affecting the broader biotechnology sector, including financing conditions and investor appetite for development-stage assets, also remain relevant. None of these milestones constitute guarantees, and the timing of event-driven data readouts can shift as studies mature.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IPHA's RSI Oscillator climbs out of oversold territory
The RSI Indicator for IPHA moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 21 of the 25 cases the stock moved higher. This puts the odds of a move higher at 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 61 of 78 cases where IPHA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on IPHA as a result. In 92 of 113 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for IPHA just turned positive on October 20, 2026. Looking at past instances where IPHA's MACD turned positive, the stock continued to rise in 35 of 50 cases over the following month. The odds of a continued upward trend are 70%.
Following a +5.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where IPHA advanced for three days, in 148 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
IPHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for IPHA moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IPHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for IPHA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.971) is normal, around the industry mean (3.498). P/E Ratio (-2.824) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (55.556) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. IPHA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IPHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment
Industry Biotechnology